IRIS Accounts Production v25.1.4.42 SC312958 Board of Directors 1.1.24 31.12.24 31.12.24 false true false false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWhSC3129582023-12-31SC3129582024-12-31SC3129582024-01-012024-12-31SC3129582022-12-31SC3129582023-01-012023-12-31SC3129582023-12-31SC312958ns15:Scotland2024-01-012024-12-31SC312958ns14:PoundSterling2024-01-012024-12-31SC312958ns10:Director12024-01-012024-12-31SC312958ns10:PrivateLimitedCompanyLtd2024-01-012024-12-31SC312958ns10:SmallEntities2024-01-012024-12-31SC312958ns10:AuditExempt-NoAccountantsReport2024-01-012024-12-31SC312958ns10:SmallCompaniesRegimeForDirectorsReport2024-01-012024-12-31SC312958ns10:SmallCompaniesRegimeForAccounts2024-01-012024-12-31SC312958ns10:FullAccounts2024-01-012024-12-31SC31295812024-01-012024-12-31SC312958ns10:Director22024-01-012024-12-31SC312958ns10:RegisteredOffice2024-01-012024-12-31SC312958ns5:CurrentFinancialInstruments2024-12-31SC312958ns5:CurrentFinancialInstruments2023-12-31SC312958ns5:Non-currentFinancialInstruments2024-12-31SC312958ns5:Non-currentFinancialInstruments2023-12-31SC312958ns5:ShareCapital2024-12-31SC312958ns5:ShareCapital2023-12-31SC312958ns5:RetainedEarningsAccumulatedLosses2024-12-31SC312958ns5:RetainedEarningsAccumulatedLosses2023-12-31SC312958ns5:NetGoodwill2024-01-012024-12-31SC312958ns5:IntangibleAssetsOtherThanGoodwill2024-01-012024-12-31SC312958ns5:PatentsTrademarksLicencesConcessionsSimilar2024-01-012024-12-31SC312958ns5:PlantMachinery2024-01-012024-12-31SC312958ns5:NetGoodwill2023-12-31SC312958ns5:IntangibleAssetsOtherThanGoodwill2023-12-31SC312958ns5:NetGoodwill2024-12-31SC312958ns5:IntangibleAssetsOtherThanGoodwill2024-12-31SC312958ns5:NetGoodwill2023-12-31SC312958ns5:IntangibleAssetsOtherThanGoodwill2023-12-31SC312958ns5:PlantMachinery2023-12-31SC312958ns5:PlantMachinery2024-12-31SC312958ns5:PlantMachinery2023-12-31SC312958ns5:CostValuation2023-12-31SC312958ns5:DisposalsRepaymentsInvestments2024-12-31SC312958ns5:CostValuation2024-12-31SC312958ns5:WithinOneYearns5:CurrentFinancialInstruments2024-12-31SC312958ns5:WithinOneYearns5:CurrentFinancialInstruments2023-12-31
REGISTERED NUMBER: SC312958 (Scotland)















Unaudited Financial Statements for the Year Ended 31 December 2024

for

PRO-HEALTH PHARMACY LIMITED

PRO-HEALTH PHARMACY LIMITED (Registered number: SC312958)






Contents of the Financial Statements
for the Year Ended 31 December 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


PRO-HEALTH PHARMACY LIMITED

Company Information
for the Year Ended 31 December 2024







DIRECTORS: M S Aziz
Mrs I Aziz





REGISTERED OFFICE: 46 -48 Clerk Street
Edinburgh
EH8 9JB





REGISTERED NUMBER: SC312958 (Scotland)





ACCOUNTANTS: NKA Chartered Certified Accountants
4 Lynedoch Place
Glasgow
G3 6AB

PRO-HEALTH PHARMACY LIMITED (Registered number: SC312958)

Balance Sheet
31 December 2024

31.12.24 31.12.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 755,317 856,967
Tangible assets 5 409,206 345,551
Investments 6 108,536 149,132
1,273,059 1,351,650

CURRENT ASSETS
Stocks 91,890 97,998
Debtors 7 1,006,619 976,503
Cash at bank 370,655 428,043
1,469,164 1,502,544
CREDITORS
Amounts falling due within one year 8 371,452 448,654
NET CURRENT ASSETS 1,097,712 1,053,890
TOTAL ASSETS LESS CURRENT
LIABILITIES

2,370,771

2,405,540

CREDITORS
Amounts falling due after more than one
year

9

(471,306

)

(549,579

)

PROVISIONS FOR LIABILITIES (102,301 ) (49,192 )
NET ASSETS 1,797,164 1,806,769

CAPITAL AND RESERVES
Called up share capital 100 100
Retained earnings 1,797,064 1,806,669
1,797,164 1,806,769

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

PRO-HEALTH PHARMACY LIMITED (Registered number: SC312958)

Balance Sheet - continued
31 December 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 25 September 2025 and were signed on its behalf by:





M S Aziz - Director


PRO-HEALTH PHARMACY LIMITED (Registered number: SC312958)

Notes to the Financial Statements
for the Year Ended 31 December 2024

1. STATUTORY INFORMATION

PRO-HEALTH PHARMACY LIMITED is a private company, limited by shares , registered in Scotland. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 0, is being amortised evenly over its estimated useful life of nil years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Patents and licences are being amortised evenly over their estimated useful life of nil years.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 25% on reducing balance and 20% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

PRO-HEALTH PHARMACY LIMITED (Registered number: SC312958)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

2. ACCOUNTING POLICIES - continued

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 19 (2023 - 14 ) .

4. INTANGIBLE FIXED ASSETS
Other
intangible
Goodwill assets Totals
£    £    £   
COST
At 1 January 2024 1,546,630 5,000 1,551,630
Disposals (2,483 ) (5,000 ) (7,483 )
At 31 December 2024 1,544,147 - 1,544,147
AMORTISATION
At 1 January 2024 694,663 - 694,663
Charge for year 94,415 - 94,415
Eliminated on disposal (248 ) - (248 )
At 31 December 2024 788,830 - 788,830
NET BOOK VALUE
At 31 December 2024 755,317 - 755,317
At 31 December 2023 851,967 5,000 856,967

5. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2024 591,483
Additions 155,064
At 31 December 2024 746,547
DEPRECIATION
At 1 January 2024 245,932
Charge for year 91,409
At 31 December 2024 337,341
NET BOOK VALUE
At 31 December 2024 409,206
At 31 December 2023 345,551

PRO-HEALTH PHARMACY LIMITED (Registered number: SC312958)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2024

6. FIXED ASSET INVESTMENTS
Other
investments
£   
COST
At 1 January 2024 149,132
Disposals (40,596 )
At 31 December 2024 108,536
NET BOOK VALUE
At 31 December 2024 108,536
At 31 December 2023 149,132


7. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Trade debtors 165,649 148,096
Amounts owed by participating interests 9,000 -
Other debtors 831,970 828,407
1,006,619 976,503

8. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.12.24 31.12.23
£    £   
Bank loans and overdrafts 80,000 80,000
Trade creditors 246,609 274,283
Taxation and social security 40,526 87,692
Other creditors 4,317 6,679
371,452 448,654

9. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
31.12.24 31.12.23
£    £   
Bank loans 471,306 549,579

Amounts falling due in more than five years:

Repayable by instalments
Bank loans more 5 yr by instal 151,306 229,579